IO Biotech, Inc. is a clinical-stage biopharmaceutical company that develops immune-modulating cancer therapies. Its lead product candidate, IO102-IO103, is in phase 2 clinical trial for melanoma and phase 1 clinical trial for lung, head and neck, bladder, and melanoma cancer. The company also develops IO112, a product candidate for the treatment of cancers.